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 Abstract
Recent studies reporting hundreds, to thousands, of circulating tumor cells (CTCs) in
the blood of cancer patients have raised questions regarding the prevalence of CTCs, as
R
enumerated by the CellSearchV CTC Test. Although CellSearch has been shown to consistently detect clinically relevant CTCs; the ability to only capture EpCAM positive
cells has led to speculation that it captures limited subsets of CTCs. In contrast, alternative approaches to CTC isolation are often cited as capturing large numbers of CTCs
from patient blood. Not surprisingly the number of cells isolated by alternative
approaches show poor correlations when compared to CellSearch, even when accounting for EpCAM presence or absence. In an effort to address this discrepancy, we ran an
exploratory method comparison study to characterize and compare the CTC subgroups
captured from duplicate blood samples from 30 breast and prostate cancer patients
using a microfiltration system (CellSieveTM) and CellSearch. We then categorized the
CellSieve Cytokeratin(CK)1/CD452/DAPI1 cells into five morphologically distinct
subpopulations for correlative analysis. Like other filtration techniques, CellSieve isolated greater numbers of CK1/CD452 cells than CellSearch. Furthermore, analysis
showed low correlation between the total CK1/CD452 cells captured by these two
assays, regardless of EpCAM presence. However, subgrouping of CK1/CD452/DAPI1
cells based on distinct cytokeratin staining patterns and nuclear morphologies elucidated a subpopulation correlative to CellSearch. Using method comparison analyses,
we identified a specific CTC morphology which is highly correlative between two distinct capture methods. These data suggests that although various morphologic CTCs
with similar phenotypic expressions are present in the blood of cancer patients, the
clinically relevant cells isolated by CellSearch can potentially be identified using nonEpCAM dependent isolation. VC 2014 The Authors. Published by Wiley Periodicals, Inc.
 Key terms
Circulating Tumor Cells; liquid biopsy; cancer phenotype characterization; CTC
cytometry; CellSearch; CellSieve

CIRCULATING tumor cells (CTCs) are cancer cells that originate from primary/metastatic solid tumors and are found transiting the circulatory system (1–4). It has
been postulated that CTCs represent a noninvasive method for treatment monitoring, subtyping, and tracking tumor progression in cancer patients (5–7). However,
isolation of CTCs is challenging because of their extreme rarity, 1–10 CTCs among
109 total blood cells, and compounded by the inherent heterogeneity of tumor cells
(2–4,7,8). CTC isolation was first reported in 1869 and although great strides were
made in increasing the efficiency of CTC isolation, a clinically validated prognostic
assay was not developed until the advent of affinity-based isolation(1–4,7,9). This clinical immunoassay, the CellSearchV CTC Test, captures CTCs from blood samples using
R
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ferrofluid nanoparticles conjugated with antibodies against the
epithelial cell adhesion molecule (EpCAM). Often called the
“standard” CTC Test, CellSearch is the only US Food and Drug
Administration (FDA) approved clinically validated CTC assay
proven to serve as an independent prognostic indicator of
patient survival for breast, prostate, and colorectal cancer
patients(1–4,9).
CellSearch captures cells using a monoclonal antibody
specific to EpCAM, and identifies CTCs using differential fluorescent antibodies to detect the presence of CK within a
nucleus-containing intact cell, and absence of CD45, as definR
ing characteristics of CTCs (1–4,8–10). Although CellSearchV
has the sensitivity to capture 1 CTC in 7.5 mL of blood, it
only captures cells in <78% of metastatic carcinomas. As
such, concerns have been raised as to whether the assay definition of CTCs is too restrictive and underestimates the number
of true CTC events (1–7,10–14). To account for this underestimation, a number of techniques are being developed to increase
capture efficiency by either altering the capture antibodies, or by
forgoing affinity capture all together (5–7,11–13,15). Although
to date, these techniques have failed to identify the CellSearch
CTC population based on presence of CK, or EpCAM, and have
shown neither correlation nor equivalency (6,7,9,11,13). Often,
it is theorized that the inability to correlate these two techniques
is a result of tumor cells losing their EpCAM expression, or
cytokeratin expression, possibly through epithelial to mesenchymal transition (EMT) processes (6,7,11,12).
Size exclusion, using microporous filters, is a technique
for isolating CTCs irrespective of their surface marker expression (5,12,13,16) that has been shown to capture far greater
numbers of CTCs than CellSearch, at times, into the thousands
per millilitre (5,12,13,15). This approach was first used over 50
years ago (15) and was recently refined for greater clinical utility (12,13). However, commercial filters used for isolating
CTCs can be quite imprecise and highly variable (5). Recent
advances in microfabrication have allowed for the commercial
production of precision microporous filters, which overcome
some previous issues, such as low porosity and high pressure
(5). We describe one such microfilter, CellSieveTM, made with
precision pores arranged in arrayed patterns, giving the filters
high porosity under low pressure (5,16). It has been shown that
a low-pressure filtration system can isolate circulating cells
while preserving fine intracellular architecture, such as cytoskeletal structures, for in depth analysis (5,16).
In this exploratory study, we isolated and enumerated
CK1/CD452 cells, with 40 ,6-diamidino-2-phenylindole positivity (DAPI1), from 30 breast and prostate cancer patients.
138
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We used duplicate samples run in parallel at different locations,
using both CellSearch and CellSieve platforms. It was found
that CellSieve filters capture greater numbers of CK1/CD452/
DAPI1 cells than CellSearch, findings that are consistent with
other studies using size exclusion (6,12,13). After identifying
CK1/CD452/DAPI1 cells and EpCAM1 CK1/CD452/
DAPI1 cells on CellSieve, neither of which showed correlation
to CellSearch, and realizing that many previous studies focusing
on EpCAM positivity in CTCs have failed to resolve the enumeration discrepancies versus CellSearch, we looked into characterizing the distinct morphological features of the CK1/
CD452/DAPI1 cells. Starting with the cytology-based FDA
definition of CTCs (e.g., positive fluorescent staining of CK 8,
18, and 19, CD452, a diameter >4 3 4 mm, and a DAPI1
nucleus 50% of which is contained within the CK border), we
found the CTCs isolated by CellSieveTM express three distinct
CK histologically definable staining patterns (e.g., filamentous,
diffuse, and punctate) (10,11,14,16–19). Additionally, the
nuclear staining patterns of CTCs isolated by CellSieve could be
distinguished histologically as either apoptotic or highly abnormal (e.g., high pleomorphism, nonuniform margins, and
unusually large size) (10,18,20). Using these criteria, we identified five distinct CK1/CD452/DAPI1 subpopulations isolated
by CellSieve. Comparison analyses found that one main CK1/
CD452/DAPI1 population was highly correlative to the CellSearch Test (R2 5 0.91, P 5 3.18*10216), and this correlation
was not dependent on EpCAM positivity. These findings suggest that microfiltration of blood samples from cancer patients
are indeed capturing a larger variety of CK1 expressing circulating cells (epithelial-like) than the CellSearch system and,
furthermore, the clinically prognostic CTC population enumerated by CellSearch may be characterized using a microfiltration
approach followed by detailed cytometric analysis. Unlike previous studies on this subject, which have never found correlations
to the CellSearch subtype, we do not attempt to determine the
underlying functional biology of these CK1 expressing cells by
comparing the expression of levels of various biomarkers. Here,
we describe that characterization and categorization of CK1/
CD452/DAPI1 cells captured by microfiltration based on their
CK and nuclear morphologic patterns numerically correlate to
the prognostically valuable CellSearch CTC subtype, which
interestingly, does not seem dependent on EpCAM staining.

MATERIALS AND METHODS
Blood Sample Collection
In total, 30 patient peripheral blood samples from breast
(n 5 21) and prostate (n 5 9) anonymized cancer patients
Correlating CellSearch and Microfilter CTCs
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through the filter (5). The filter is washed, postfixed, and permeabilized. The captured cells are stained with an antibody
cocktail consisting of FITC-anti-Cytokeratin 8, 18, 19; Phycoerythrin (PE) conjugated EpCAM; and Cy5-anti-CD45 (5)
(Fig. 2). Filters are then washed, placed onto a microscope
slide and cover-slipped with Fluoromount-G/DAPI (Southern
Biotech). An Olympus BX54WI Fluorescent microscope with
Carl Zeiss AxioCam was used to image cells. Exposures were
preset as 5 sec (Cy5), 2 sec (PE), 100–750 msec (FITC), and
10–50 msec (DAPI) for equal signal comparisons between
cells. A Zen2011 Blue (Carl Zeiss) was used to process the
images.

Figure 1. Flow chart of CTC identification using the CellSieveTM
system. 7.5 mL peripheral blood containing 109–10 cells is filtered. 103–4 cells are retained on the filters and are stained with
DAPI, anti-CK and anti-CD45 antibodies. Stained cells on the filter
are scanned for CD45 signal. 102–3 of the cells are CD452.
Remaining cells are then scanned for CK1. 10–100 of the cells
are CD452 and CK1. CK1 CTCs are imaged and subtyped by a
trained cytologist into five distinct subpopulations based on cytokeratin and DAPI staining patterns.

were supplied through a collaborative agreement with Fox
Chase Cancer Center (FCCC) and University of Maryland Baltimore (UMB), with written informed consent and according
to the local Institutional Review Board (IRB) approval at each
institution. In addition, 30 nonblinded healthy volunteer
blood samples were collected in CellSave preservative tubesTM,
with written informed consent and IRB approval by Western
Institutional Review Board. Anonymized blood samples were
drawn in tandem into two CellSave tubes (9 mL). Within
72 h, one tube (7.5 mL) was used to enumerate CTCs using
CellSearch at FCCC. The second tube (7.5 mL) was used to
enumerate CTCs using CellSieve microfiltration at UMB or
Creatv MicroTech. Results and patient identification from
institutions were not shared or communicated until completion of the study.
CellSieve Microfilter CTC Enumeration
Each CellSieve Microfiltration Assay isolates CTCs based
on size exclusion and identifies CTCs based on the histological
cell architecture of cytokeratin, and nuclear morphologies
(5,16). An overview of the process is shown in Figure 1. The
assay and reagents have been previously described (21).
Briefly, each assay is supplied with a CellSieve microfilter
(160,000 pores each at 7 mm in diameter arrayed on a 9 mm
area), Prefixation buffer, a Postfixation buffer, a Permeabilization buffer, and an antibody cocktail (5). The low-pressure
system uses a filter holder assembly attached to a regulated
vacuum set at 5 mL/min. Peripheral blood (7.5 mL), collected
in a CellSave tube is diluted in a prefixation buffer and drawn
Cytometry Part A  87A: 137144, 2015

CellSearch CTC Enumeration
The CellSearch system was run following the Janssen protocols at FCCC. Immunomagnetic enrichment of CTCs using
the CellTracksTM AutoPrep System has been previously
described (22). Peripheral blood samples collected in CellSave
Preservative tubes were maintained at ambient temperature.
CellSearch Epithelial Cell kits (Janssen Diagnostics) were used
for the isolation of CTCs. Isolations was performed on the
R
CellTracks AutoPrepV System (Janssen Diagnostics). Data was
R
collected and analyzed on the CellTracks Analyzer IIV (Janssen
Diagnostics).
Briefly, antipan cytokeratin (CK 8, 18, 19)-PE, antiCD45-APC, and DAPI (CellSearch Epithelial Cell kit reagents)
were used to differentially label the CTC enriched product.
Ferrofluid nanoparticles conjugated with anti-EpCAM antibodies capture CTCs from 7.5 mL of blood and are magnetically
separated. Cells are washed, permeabilized, labeled with fluorescent antibodies, resuspended in Cell Fixative then loaded
into a cartridge held in a magnetic holder (MagNest) which
aligns the ferrofluid-captured cells. The Magnest is placed into
R
a CellTracks Analyzer IIV and the fluorescently labelled cells are
imaged. Images are sorted using computer-assisted software
selecting and presenting CK1 and DAPI1 events. A technician
selects cells meeting the FDA criteria for CTCs, for example,
(1) expressing CK, (2) lacking CD45, and (3) containing a
DAPI1 nucleus 50% which is contained within an intact CK1
perimeter (Supporting Information Fig. 1).

STATISTICAL METHODS
Linear regression plots were made using the enumerated
counts from all subtypes of CK1/CD452 cells identified
using CellSieve and the CTCs enumerated by CellSearch.
Spearman correlation coefficients were calculated for each
CK1/CD452 subtype using MATLAB R2013A. Power analysis for sample size was calculated using previously published
CVs using MATLAB R2013A (1,5,23,24). In addition, linear
regression plots, slopes, and correlative values were also calculated for breast, and prostate, cancer patient samples (Fig. 3
and Supporting Information Fig. 2).

RESULTS AND DISCUSSION
Since the CellSearch system utilizes a highly specific
EpCAM-based approach to capture CTCs, it has been argued
139
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Figure 2. Subpopulations of CTCs based on cytological features of cytokeratin and DAPI on CellSieveTM. (A–H) CTCs categorized as
PDCTCs with (A, E) filamentous cytokeratin. (B, F) The nuclei are malignant, appearing with nuclear inclusions and margin irregularities.
(C, G) Merged images. (D, H) Strong EpCAM1 expression. (I–P) CTCs categorized as EMTCTCs with (I, M) diffuse cytokeratin patterns. (J,
N) Nuclei appears malignant with irregular nuclear contours but smooth margins and a regular oval shape. (K, O) Merged images. (L, P)
Low/negative EpCAM expression. (Q–T) CTC categorized as EACTC with (Q) punctate cytokeratin. (R) Nucleus appears as malignant with
an abnormal salt-and-pepper pattern. (S) Merged image. (T) EpCAM1 expression. (U–X) CTC categorized as LACTC with (U) punctate
cytokeratin. (V) Nucleus also appears punctate, or blebbing. (W) Merged image. (X) Low/negative EpCAM expression. Scale bars, 10 mm.

that it is insensitive to circulating epithelial cells which do not
express EpCAM on their cell surface. Therefore, it is concluded that this technique has limited utility on broader
patient cohorts with failings in capturing and identifying cancer stem cells which have undergone EMT, a heterogeneous
process with no standardized definition (11,13). Alternative
techniques, such as size based isolation, whole blood cell
smears, electrophoresis, so forth, attempt to increase sensitivity of CTC capture, typically while sacrificing specificity
(5–7,11–13,15). Not surprisingly, less stringent techniques
have been shown to capture far greater numbers of CK1 and
EpCAM1 expressing cells from the blood of cancer patient
samples, at times numbering thousands of CK1, or EpCAM1
expressing cells per millilitre (5–7,11–13,15). The greater
number of CK1 expressing cells captured by these techniques
is argued to be a result of greater efficiency of their
approaches. However, the same clinically validated data provided by CellSearch has yet to be reproduced by these alternative approaches and attempts to account for these
discrepancies by evaluating the functional biology of the CK1
cell types using additional biomarker information, such as
140

EpCAM presence, have not yet yielded improved correlations
with CellSearch (6,7,10,12,13).
In an effort to reconcile the discrepancies between CK1
expressing cells captured using filtration techniques, and the
prognostically significant enriched CK1 expressing cells identified as CTCs via CellSearch, we performed a detailed examination of all CK1 expressing cells captured by the CellSieve
microfiltration system. To directly compare the two techniques,
we only examined staining patterns of the standard CellSearch
detection markers, including intact cells with cytokeratin,
CD45, EpCAM, and nuclear DAPI, and not by adding additional marker systems nor including CK1 particles (10).
Cytokeratins are intermediate filament proteins expressed
by epithelial derived cells and are prevalent in transformed
epithelial cells (17), such as CTCs (1,9,11,14,19). These structures are extremely fine (10 nm diameter) and their morphologies can give information regarding apoptosis, structural
integrity, and anaplasia (14,17,19,25). Since the CellSieve system has been shown to preserve internal cellular structures,
detailed analysis of the distinct CK1 filament architecture can
be performed (5,16).
Correlating CellSearch and Microfilter CTCs
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Figure 3. Correlations of CK1 subpopulations identified by CellSieveTM filters versus enumeration by CellSearchV. (A) Correlations
between the CTC subcategories by CellSieve compared to CTCs by CellSearch. (B) Linear regression curve plots between Total CK1 cells
versus CellSearch showing a low correlation. (C) Linear regression curve plots between PDCTCs versus CellSearch, showing a high correlation. Slopes are found in Supporting Information Figure 2.
R

The distinct CK1 staining pattern of cells captured by
CellSieve can be readily identified as filamentous, diffuse, and
punctate and form the basis of CTC subclassification used in
this study (Fig. 2). Filamentous CK is the classical and established example of epithelial intermediate filaments, with fibril
like structures traversing although the interior of a cell (Fig.
2A and 2E) (14,17,19). Diffuse CK is defined by a weak CK
staining without observable filamentous patterns, usually this
pattern is associated with epithelial-mesenchymal transition,
although no universal definition of EMT transition currently
exists (Fig. 2I and 2M) (11,14,17). Punctate CK staining can
be attributed to the collapse of the cytoskeletal structure, in
the early stages of apoptosis, which results in retraction of the
cytokeratin filaments, referred to as blebbing (Fig. 2Q and
2U) (10,25). Cytokeratin blebbing has also been described in
the CellSearch Test Analyzer and typically counted as a CTC,
although disagreements in the definitions between intact
“granular” CTCs and cell particles do exist (9,10).
Nuclear morphology is another criteria used in identifying, grading, and classifying cancer cells in both cancer biopsies and on the CellSearch system (9,10,18). After filtration,
we identify abnormal nuclear patterns typically seen in tumor
cells (e.g., pleomorphism, nonuniform margins, unusually
large size) (Fig. 2B, 2F, 2J, 2N, 2R, and 2V) (18,20). These
nuclear variations are a prerequisite for morphologically classifying CTCs and, in cases of punctate CK patterns, we used
the presence of these variations to identify cells undergoing
Cytometry Part A  87A: 137144, 2015

early apoptotic or late apoptotic events. In early apoptotic
CTCs, the CK1 staining is punctate; however, the nucleus is
intact (Fig. 2Q and 2R) (18,20). In late apoptotic CTCs, the
CK staining is punctate and the progressive apoptotic process
has broken the nucleus apart, also called nuclear blebbing or
punctate (Fig. 2U and 2V) (25). In either case, a DAPI positive
signal within a CK1 signal is defined as a CTC on the CellSearch Test Analyzer (9,10).
Based on the three CK1 staining patterns (filamentous,
diffuse and punctate) and two nuclear staining pattern
(malignant and punctate), we have identified four distinct
subpopulations which make up the total CK1/CD452
expressing cells classified as CTCs isolated by CellSieve:
1. Pathologically definable CTCs (PDCTC): (1) have strong
filamentous CK1 signal, (2) have a DAPI1 nuclei with
malignant pathologies (Fig. 2A–2H).
2. Epithelial-Mesenchymal transition-like CTCs (EMTCTC): (1)
have diffuse/nonfilamentous and weak CK1 signal, (2) have
a DAPI1 nuclei with malignant pathologies (Fig. 2I–2P).
3. Early Apoptotic CTCs (EACTC): (1) have a punctate CK1
signal, (2) have intact DAPI1 nuclei with malignant pathologies (Fig. 2Q–2T).
4. Late Apoptotic CTC (LACTC): (1) have a punctate CK1 signal, (2) have a punctate nuclear DAPI1 staining (Fig. 2U–2X).
The CK1/CD452 cells in the four subpopulations
ranged from high EpCAM positivity to low/negative
141
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Table 1. CTCs enumerated by CellSearch and CK1 subpopulations identified by CellSieveTM
R
V

LACTC
CELLSIEVETM

EMTCTC
CELLSIEVETM

ATYPICAL
CK1 CELLS
CELLSIEVETM

TOTAL CK1
CELLS CELLSIEVETM

0
0
0
0
0
2
0
0
0
0
0
2
0
3
1
2
0
1
0
16
18
2.1 6 5.0
0

0
5
2
2
0
3
0
0
0
0
10
2
18
1
17
2
0
0
0
0
6
3.2 6 5.4
1

45
0
0
2
0
0
1
6
0
1
0
0
27
0
3
11
2
4
0
14
0
27.6 6 21.4
21

55
10
14
7
74
20
9
6
22
17
15
17
33
26
70
21
70
11
21
34
28
5.5 6 11.2
1.0

100
15
18
13
75
28
10
20
22
18
26
24
83
34
95
41
84
25
30
76
142
46.6 6 37.0
28.0

2
0
1
3
0
0
6
8
34
6.0 6 10.9
2.0

0
2
0
0
5
18
6
0
31
6.9 6 10.7
2.0

0
0
0
3
0
12
5
0
23
4.8 6 7.9
0.0

0
0
4
1
0
0
0
2
0
23.7 6 15.7
19.0

5
19
62
18
24
17
23
18
27
0.8 6 1.4
0.0

7
21
67
25
29
47
40
28
115
42.1 6 32.2
29.0

7.5 6 16.9
3.0

3.6 6 7.4
0.0

3.7 6 6.1
0.5

26.4 6 19.6
20.5

4.1 6 9.6
0.0

45.3 6 35.1
28.5

CELLSEARCH

PDCTC
CELLSIEVETM

EACTC
CELLSIEVETM

BC1
T2/N1/M1
BC2
TX/NX/MX
BC3
TX/NX/M1
BC4
T2/N1/M0
BC5
TX/N2/M0
BC6
TX/N2/M0
BC7
T4/N3/M0
BC8
T3/N1/M0
BC9
T4/N3/M1
BC10
T4N3/M0
BC11
TX/NX/M1
BC12
T2/N1/M1
BC13
T4/N2/M0
BC14
T4N3/M0
BC15
TX/NX/M1
BC16
TX/NX/M1
BC17
TX/NX/M1
BC18
T2/N1/MX
BC19
TX/NX/M1
BC20
T4/N3/M0
BC21
T1/N2/M0
Average 6 SD
Median

0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
3
8
11
24
112
7.7 6 4.6
0

0
0
2
2
1
3
0
8
0
0
1
3
5
4
4
5
12
9
9
12
90
8.1 6 19.2
3.0

PC1
T2/N0/M0
PC2
TX/NX/M1
PC3
TX/NX/M1
PC4
T3NX/MX
PC5
T2/N0/M0
PC6
T3/N1/M1
PC7
T3/N0/MX
PC8
T2/N1/M0
PC9
TX/NX/M1
Average 6 SD
Median

0
0
1
4
7
9
10
10
73
12.7 6 23.0
7.0
9.2 6 23.8
1.0

PATIENT

Total average
Total median

TNM

R
V

CTCs isolated from duplicate samples of blood from prostate (PC) and breast (BC) cancer patients. The rows from left to right show
patient number, Classification of Malignant Tumors (TMN) and the number of CTCs identified by CellSearch. Right six rows show the
number of CTC subpopulations, and the total number of CK1 cells identified by CellSieve.

positivity (Fig. 2D, 2H, 2L, 2P, 2T, and 2X), but were not a
driving factor in concordance (Supporting Information Fig.
2). CK1/CD452 cells that could not be categorized into these
four subpopulations were classified as “Atypical CK1 cells”
and not counted as CTCs for this study (Supporting Information Fig. 3). These cells included CK1/CD452 cancer associated macrophage-like cells (CAMLs) (16) (Supporting
Information Fig. 3, Column A) and DAPI1 and CK1 cells
without visible cytoplasm (Supporting Information Fig. 3, Column B). Other CK1/CD452 events not included in this study,
142

as they do not meet the criteria of a CTC, include (1) CK1/
CD452 events with no DAPI signal (Supporting Information
Fig. 3, Column C) and (2) CK1/CD452 cells which were identified as noncancerous (e.g., granulocytes, macrophages, so
forth) by a pathologist (Supporting Information Fig. 3, Column D). Additionally, cell clusters/microemboli of 2 were
counted as one CTC (Supporting Information Fig. 3, column
E), following equivalence to CellSearch enumeration (1–4,9).
In Table 1, the 4 CK1/CD452 CTC subpopulations,
Atypical CK1 cells and the total CK1/CD452 cells are shown
Correlating CellSearch and Microfilter CTCs
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Figure 4. Percentage of EpCAM positivity in the CK1 populations. CK1 cells isolated by CellSieveTM were further categorized
by visual presence of EpCAM. The percentage of EpCAM positive
cells in the CK1 cells for each subcategory is listed, as is the difference in EpCAM percentage in breast samples and prostate
samples. Slopes and correlations of EpCAM subcategories are
found in Supporting Information Figure 2D, error bars indicate
standard error of the mean.

in comparison to CellSearch enumeration, for the 30 duplicate
patient samples. CellSieve captured 979 CK1/CD452 cells
from 21 breast cancer patient blood samples compared to 162
CTCs captured by CellSearch. Additionally, CellSieve captured
379 CK1/CD452 cells from 9 prostate cancer patients, compared to 114 by CellSearch. No CTCs, from the 30 healthy volunteer blood samples, were found on the CellSieve system.
These data support previous publications regarding greater
CTC capture from patient blood samples using size exclusion
(5,12,13).
To compare the two assays, we ran method comparison
analyses using linear regression plots with correlation significance (23). We chose a sample size of 30 which gives the statistical power necessary to detect differences smaller than the
intrinsic variability range of the CellSearch Test (1,5,23,24).
When comparing regression plots between the total CK1/
CD452 population isolated by CellSieve versus CellSearch we
found that the cells were not equivalent, whether we included
EpCAM presence or not (Fig. 3 and Supporting Information
Fig. 2). This lack of equivalency matches most previous studies regarding the comparison of CellSearch to other techniques (6,7,12,13,26). However, when we compared individual
CellSieve subpopulations with CellSearch, we found that the
PDCTC subgroup showed significant correlation with CellSearch (R2 5 0.9107, P < 0.0001; Fig. 3A and 3C). Additionally, the inclusion of EACTCs with the PDCTCs gave the best
equivalency, higher than the inclusion of PDCTC with
EpCAM1 expression (Supporting Information Fig. 2A and
2D). This data suggests that the PDCTC subpopulation,
regardless of EpCAM presence, is most statistically correlated
to CellSearch, while the other CK1/CD452 cells are not. Furthermore, our data suggests that although the CellSearch sysCytometry Part A  87A: 137144, 2015

tem relies on capturing EpCAM1 cells for isolating CTCs;
correlation of this clinically relevant CTC subtype, identified
using microfiltration, is primarily dependent on cytokeratin
and nuclear morphologies, and not EPCAM expression (Supporting Information Fig. 2).
By analyzing the presence of EpCAM in the PDCTCs cells,
our data appears to be in agreement with staining studies of
primary biopsies which analyzed EpCAM expression. This
study showed that 99% of prostate carcinomas and 74% of
breast carcinomas were EpCAM positive (8). Our data shows
that the percentage of EpCAM positivity in breast PDCTCs is
68% and 90% in prostate PDCTCs (Fig. 4). The EpCAM data
also seems to agree with the theories regarding EMT cell transition as there was less EpCAM present in cells that also have
diminished CK staining, the EMT-like CTCs. However, as there
in no universal definition of EMT, further analysis of the CTCs
exhibiting these characteristics needs to be performed when
specific markers of EMT cells have been identified (6,11,12,14).
Once method correlations were established, we ran a preliminary evaluation of the prognostic significance of the CK1
categories using 5 CTCs/sample as a threshold for patient
overall survival (OS). The criteria for clinical utility, for breast
and prostate cancers, is the cut off value of 5 CTCs/sample, <5
showing longer OS than 5 CTCs (2–4). Supporting Information Figures 4 and 5 shows the survival of the 26 patients that
remained on study for a 24 month period. Using the 5>
threshold we found that CellSieve PDCTCs and CellSearch
matched in 23 of the 26 patients, and in the three instances
where the methods differed, there was an observed change in
the survival outcome (Supporting Information Fig. 4). Additionally, both EMTCTCs and EpCAM positive PDCTCs had
some lower correlations to CellSearch, and both groups also
showed some difference in overall survival for patient cohorts
using the 5> cell criteria (Supporting Information Fig. 5).
Although this data implies differences in outcome between
patient cohorts, the data set is too small to draw any statically
relevant conclusions. It does, however, suggest that additional
larger studies may be warranted to determine if these survival
trends continue to differentiate patient populations.
For many years, the goal of CTC work has revolved
around the concept of using blood as a “liquid biopsy” for
cancer diagnosis, prognosis, and treatment response. Generally, histological review of biopsies define the presence of
tumor cells using morphological criteria based on organ specific histopathological grading schema describing cellular features (e.g., nuclei abnormalities, mitotic proliferation,
hyperactive Golgi, so forth). However, current CTC capture
techniques lack the ability to provide adequate numbers of
circulating epithelial cells in a format where standard histological staining can be applied, and reviewed by a pathologist.
Here, we demonstrate that multiple populations of CTCs can
be identified by histopathological staining patterns of CK and
DAPI using filter-based isolation. These preliminary data suggest that CTCs with malignant nuclear morphologies and filamentous cytokeratin are, at least numerically, the same cells
identified using CellSearch. These findings support the
hypothesis that both CellSearch and CellSieve microfiltration
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are capable of identifying a similar number of highly specific
and clinically relevant CTC subtypes.
As CTC isolation methods have become more varied and
our biological understanding become greater, the defining criteria for what cells meet the designation of a CTC has become
less stringent (10,11,14). Complicating the criteria of CTCs is
the knowledge that cancer cells can undergo EMT, which has
no universal definition, although generally described by the
down regulation of epithelial proteins, such as EpCAM and
cytokeratin. As there in no scientific consensus in the EMT
definition, and not within the scope of this manuscript, we
did not attempt to identify the EMT processes in cells, only
describe EMT-like cells by the visual loss of filamentous structure (10,11,14).
When assessing new technologies one must determine
the proposed usage of the capture events. If the intent is to
collect product for downstream mutational analysis, this is
quite different than using a new technique as a prognostic
indicator of overall survival, such as CellSearch. The primary
result of many CTC capture methods is to show discordance
with the clinical validity of CellSearch, by virtue of increased
CTC number (23). However, a fact which is largely ignored by
comparative technologies is the fact that CellSearch captures
numerous cytokeratin positive particles which are known to
provide prognostic value, but are discluded by the morphological identification of a trained operator (9,10,22). Groups
typically bypass the morphological criteria, and explain this
difference in CTC number between their techniques and CellSearch through the use of additional biomarkers, for example,
EMT markers, apoptotic markers, and proliferation markers
(6,7,11–13). However, to date, studies focusing on these functional biological markers have lacked the ability to correlate to
CellSearch and, as such, have offered few insights into the
CTC subpopulation that CellSearch enriches for (6,7,12,13).
In this study, rather than focusing on the identification of the
biological differences between two CTC capture technologies
using differing biomarkers, we provide the first example of
matched samples, using accepted markers, which can replicate
the data demonstrated using the CellSearch system. Our data
suggests that size exclusion techniques coupled with characterization of specific staining morphologies might be used to
identify a validated and clinically relevant CTC subpopulation
for breast and prostate cancer. This exploratory study reveals
an opportunity to now expand and define the clinical relevance of additional CTC subpopulations captured by nonEpCAM-based techniques and better understand the CTCs
CellSearch captures.
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